Find an expert

Scott Beatson is an Associate Professor and NHMRC Career Development Fellow at The University of Queensland (UQ). He specializes in bacterial pathogenomics: using whole-genome sequencing to investigate transmission, pathogenesis and antibiotic resistance in bacteria. Recent work from his group includes genomic analyses of pandrug resistant enterobacteriaceae and the multidrug resistant Escherichia coli ST131 pandemic clone. He was awarded a PhD from UQ for his work in bacterial pathogenesis in 2002 and developed his career in bacterial genomics in the United Kingdom with the support of fellowships from the Royal Commission for the Exhibition of 1851 (University of Oxford) and the UK Medical Research Council (University of Birmingham). Since returning to Australia he has held fellowships from both the NHMRC and ARC and has led a successful research group in the School of Chemistry and Molecular Biosciences at UQ since 2008. He is also a member of the Australian Infectious Diseases Research Centre and the Australian Centre for Ecogenomics. In 2016 he received the Frank Fenner Award from the Australian Society for Microbiology in recognition of his contribution to microbiology research in Australia.

Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.

Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.

She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.

Dr Seth Cheetham is an ARC Discovery Early Career Award Fellow and group leader at the Australian Institute for Bioengineering and Nanotechnology. He is also the Deputy Director of the BASE facility, Australia's leading mRNA manufacturing hub. He completed his PhD at the University of Cambridge, supported by the Herchel Smith Research Studentship. Seth is a molecular biologist and geneticist with a focus on mRNA drugs, synthetic biology and epigenetics. He has authored 22 publications, including twelve as a first author and four as a corresponding author. He has published in some of the most influential molecular biology journals including Science, Molecular Cell, Nature Reviews Genetics , Genome Biology and Nature Structural and Molecular Biology. His work has attracted > $10M in funding from an ARC DECRA (2022), NHMRC Fellowship (2019), MRFF grants, UQ HERA Grant, a Cancer Australia Grant (2021), Mater Foundation seeding grant (2019), a UQ ECR grant (2019) and the UQ Genome Innovation Hub (2020). In 2021 Seth was awarded the Genetics Society of Australasia Alan Wilton ECR awarded for his research in the field of RNA and epigenetics.

Dr Peter Crisp is an expert in crop genomics, epigenomics and molecular genetics. He leads a research group in the School of Agriculture and Food Science. His research group seeks to understand the contribution of epigenetics to heritable phenotypic variation in crop plants, focusing on cereals including barley, sorghum, wheat and maize. This includes the development of methods to harness epigenetic variation for crop improvement; understanding the role of epigenetics in stress responses and using innovative epigenomic approaches to distill large genomes down to the relatively small fraction of regions that are functionally important for trait variation. Research in the Crisp Lab spans both wet lab and computational biology providing a powerful platform to integrate genetic, genomic and biotechnological approaches.

Check out the CrispLab website here

Follow Dr Crisp on Twitter: @pete_crisp

Dr. Forutan is an internationally recognized Researcher. Her research area includes understanding the bovine genome and epigenome, discovering causative mutation underlying economic important traits such as fertility, understanding the way genes turn on and off, investigating different methodologies to improve the accuracy of genomic prediction, and optimizing methods for predicting genetic diversity and inbreeding. Her future research career vision is to make a significant contribution to creating new knowledge in the field of quantitative genetics that can help to improve efficiency and resilience in Livestock.

After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (London, UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF-pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill.

In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival. He has been awarded both internal and NHMRC grant funding to support these studies. Since 2019, Dylan has held an Honorary Associate Professorship at UQ

As of early 2021, Dylan has authored one conference report, two editorials, two book chapters, six reviews and 31 original research articles. He is first or last author on 20 of these publications and 27 of his publications have been cited at least 10 times. According to CiteScore, since 2010, 53% of his articles have been published in journals ranked in the top 10% and 19% of hispublications are in the 10% most cited publications worldwide.

Dr Pingping Han is currently leading the Epigenetic Nanodiagnostics and Therapeutics Group within the Centre for Orofacial Regeneration, Reconstruction and Rehabilitation (COR3), at the UQ School of Dentistry. Dr Han received her PhD in Biomedical Engineering from the Queensland University of Technology (QUT) in 2014. Dr Han's current research focuses on three themes: a) salivary diagnostics for periodontal disease, b) “cell-free” regenerative therapy for periodontal tissue engineering and c) cellular nano-mechanics on different modified biomaterial substrates.

Alesha Hatton is a postdoctoral research fellow specializing in statistical genetics and genetic epidemiology at the Institute for Molecular Bioscience, University of Queensland. Currently, her research focuses on understanding the genetic and environmental aetiology underlying complex traits through use of Mendelian randomization and statistical genetics methodologies. Her PhD was in systems genomics, applying quantitative genetics methods to investigate the role of DNA methylation in complex trait variation. Alesha has a bachelor’s degree in medical mathematics from the University of Wollongong (2016) and previously was employed as a statistician at the South Australian health and Medical Research Institute.

Dr. Nguyen is an expert in applying long-read Oxford Nanopore Sequencing Technologies (ONT) in agriculture, particularly livestock and other sectors. Her groundbreaking contributions include being the pioneer in sequencing the genomes of Brahman and Wagyu cattle, developing an innovative epigenetic clock for age prediction in cattle, and successfully implementing ONT portable sequencers for Blockchain traceability systems in Australia.

As a leader in the field, Dr. Nguyen spearheads the use of ONT long-read technology to scaffold genome assemblies in livestock, plants, protists, and insects. Her multidisciplinary expertise in molecular biology, advanced genomics, and animal sciences also empowers her to explore causative markers for commercial SNP arrays and identify significant DNA variants from low-coverage sequencing data sets.

Dr. Nguyen's exceptional achievements and expertise have been acknowledged through the prestigious ARC Industry Fellowship, recognising her as a promising early career researcher. Her work has significantly contributed to advancing genomic research in agriculture and has opened new avenues for utilising ONT sequencing technologies across diverse domains.

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland. He is leading the Genomics and Machine Learning (GML) lab to study neuroinflammation and cancer-immune cells at single-cell resolution and within spatial morphological tissue context. His research interest is about revealing gene and cell regulators that determine the states of the complex cancer and neuronal ecosystems. Particularly, he is interested in quantifying cellular diversity and the dynamics of cell-cell interactions within the tissues to find ways to improve cancer diagnosis or cell-type specific treatments or the immunoinflammation responses that cause neuronal disease.

Using machine learning and genomic approaches, his group are integrating single-cell spatiotemporal sequencing data with tissue imaging data to find causal links between cellular genotypes, tissue microenvironment, and disease phenotypes. GML lab is also developing experimental technologies that enable large-scale profiling of spatial gene and protein expression (spatial omics) in a range of cancer tissues (focusing on brain and skin cancer) and in mouse brain and spinal cord.

Dr Quan Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship (2019-2021), and is currently a National Health and Medical Research Council leadership fellow (EL2). He has published in top-tier journals, including Cell, Cell Stem Cell, Nature Methods, Nature Protocols, Nature Communications, Genome Research, Genome Biology and a prize-winning paper in GigaScience. In the past three years, he has contributed to the development of x8 open-source software, x2 web applications, and x4 databases for analysis of single-cell data and spatial transcriptomics. He is looking for enthusiastic research students and research staff to join his group.

I graduated from The University of Tasmania, and received my PhD in Developmental Biology from The University of Queensland in 2003. My PhD, performed at the Institute for Molecular Bioscience with Prof. Melissa Little, centred on understanding the cellular and molecular mechanisms underlying embryonic kidney development. My first postdoc was performed with Prof. Christine Holt at The University of Cambridge, UK, where I studied the mechanisms by which axonal growth cones navigate to their targets in the brain, using the frog Xenopus laevis as a model system. In my second postdoctoral position, with Prof. Linda Richards at the Queensland Brain Institute at The University of Queensland, my work focussed on understanding the molecular mechanisms of neural progenitor cell specification in the developing cerebral cortex. In late 2010, I took up a joint position with the Queensland Brain Institute and The School of Biomedical Sciences (SBMS) to continue my research into the mechanisms underlying neural stem cell differentiation. I have held numerous fellowships during my career, including an NHMRC Howard Florey Fellowship, an NHMRC CDF and an ARC Future Fellowship. I currently hold a continuing Teaching and Research position within SBMS, and am currently the Director for Higher Degree Research Training at SBMS.

My group's research uses large-scale genomic data to address knowledge gaps in disease, with a particular focus on cardiovascular disease.

Research programme

1. Cardiovascular disease research using big-data and genomics: with the goal of improving prevention and treatment of cardiovascular disease. By focusing on underrepresented groups, including women, my research aims to also address inequity in cardiovascular outcomes. I am the lead of the South Asian Genes and Health in Australia (SAGHA) study, which aims to increase representation of Australian South Asians in cardiovascular and genomics research. See saghaus.org for further details.

2. Drug genomics: I'm interested in using genomic approaches to predict drug effects, including identification of drug repurposing opportunities as well as identifying unknown adverse effects of medication.

3. Liver transplant research: In this collaboration with the QLD Liver Transplant Unit, we are using genomics to understand the effect of normo-thermic perfusion (a new organ storage method) on liver function, with the long-term goal of improving our ability to predict transplant outcomes.

Career summary: I was awarded my PhD from University College London (UK) in cardiovascular genetics. I began my post-doctoral fellowship under the mentorship of Prof Peter Visscher at the Queensland Brain Institute in 2013. Between 2016-2018, I was the lead analyst for the International Heart Failure Genetics Consortium (HERMES). In 2018, I was awarded an NHMRC Early Career Researcher Fellowship to investigate the relationship between cardiovascular and brain-related disorders using large-scale genetic and genomic data, under the mentorship of Prof Naomi Wray. I currently hold a National Heart Foundation Future Leader Fellowship.

Recognition:

2024 Australian Academy of Science Ruth Stephens Gani Medal for outstanding contribution to genetics research

2023 1 of 5 global finalists for the Nature Inspiring Women in Science (Scientific Achievement Award)

2023 Lifesciences QLD Rose-Anne Kelso Award

2023: Named in Australia's Top 25 Women in Science by Newscorp

2022 Queensland Young Tall Poppy Award

2022 UQ Foundation Research Excellence Award

2021/2022 Australian Superstar of STEM,

2020 Genetic Society of Australasia Early Career Award

2020 Women in Technology Rising Star Science Award

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

My research interests are at the intersection of plant developmental genetics, functional genomics, and molecular and systems biology, following my doctoral and postdoctoral training in the USA. The research effort in my group is focused on harnessing transformative genomics technology to understand the genetics of plant development, and to discover regulatory mechanisms coordinating plant growth and development. We utilize a variety of plant species in our research, from the model plant organism Arabidopsis to grain and horticultural crops like wheat, mango, avocado and macadamia. We employ a range of techniques based on high throughout DNA sequencing to explore gene expression, chromatin accessibility and modifications from single cell to whole plant levels, bioinformatics and computational biology tools to infer genetic components of gene regulatory networks, as well as gene editing technology to evaluate phenotipic consequences of perturbations in gene regulatory networks.

Professor Wolvetang is an international leader in the area of pluripotent stem cell biology and human functional genomics. he initiated and leads Cell Reprogramming Australia, a collaborative framework that facilitates induced pluripotent stem cell research in Australa and is co-director of the UQ Centre in Stem Cell Ageing and Regenerative Engineering (StemCARE). He has extensive expertise in reprogramming somatic cells, differentiation and tissue engineering with adult, embryonic and induced pluripotent stem cells, genome manipulation with CRISPR, molecular biology, transcriptome analysis, high content image analysis, development and use of microfluidic devices for cell analysis, nanoparticle and scaffold design and delivery, and stem cell and cell-free regenerative medicine approaches.Professor Wolvetang has been instrumental in establishing and enabling the technology for derivation of induced pluripotent stem cells across Australia. Professor Wolvetang made the strategic decision to focus on the generation of induced pluripotent stem from patients with neurological and cardiac disorders because live human cells from such patients can usually not be obtained whereas induced pluripotent stem cells have the ability to generate every cell type of the human brain in unlimited amounts and can recapitulate the disease in the dish. Induced pluripotent stem cells combined with emerging technologies such as CRISPR-based genome editing offers a unique opportunity to study the role of individual genes and combinatorial gene regulatory pathways in the eatiology of monogenic and complex brain disorders. Indeed, combined with RNA-seq and organoid generation we are now for the first time able to gain insight into gene regulatory pathways operational in individual brain cell types of healthy and diseased individuals, investigate the connectivity and function of cells, as well as pinpoint where and when during early development such deregulated pathways lead to pathological changes. Induced pluripotent stem cells further not only provide insight into the underlying pathogenesis of neurological disorders but also constitute a valuable drugscreening platform and, following CRISPR-based gene correction, can form the basis of patient specific cellular therapies for currently incurable diseases.

Professor Wolvetang received his PhD in 1992 from the Department of Biochemistry, University of Amsterdam for his original work on peroxisomal disease (6 papers). He undertook postdoctoral studies at the Department of Biochemistry and the Institute for Reproduction and Development of Monash University, investigating apoptosis, Down syndrome and Ets transcription factors, respectively, obtaining the first evidence for an intra-chromosomal regulatory loop on chromosome 21 involving Ets2 (3 papers), and revealing the role of p53 in immune-suppression in Down syndrome (Hum Mol. Genetics). He then joined Prof Martin Pera in the Australian Stem Cell Centre in 2003 to pioneer human embryonic stem cell research in Australia, resulting in a first author Nature Biotechnology paper in 2006 identifying CD30 as a marker for genetically abnormal hESC (72 cites). He was appointed group leader of the Basic human stem cell biology laboratory in the ASCC research laboratory and senior lecturer in the Department of Anatomy and Cell biology until he accepted his current position as an independent group leader at the AIBN and Professor in stem cell biology at the University of Queensland in 2008. There he started to generate integration-free induced pluripotent stem cells from human neurological diseases such as ataxia-telangiectasia (Stem cells translational medicine). In recognition of his leadership role in this area of research he was appointed leader of the “Reprogramming and Induction of pluripotency” Collaborative Stream of the Australian Stem Cell Centre until the end of that initiative in 2011, coordinating collaborative research between eight stem cell laboratories across Australia. He subsequently initiated and is now the president of Cell Reprogramming Australia, a collaborative framework aiming to facilitate and accelerate iPS cell research in Australia and the Asia pacific region and inform the general public about reprogramming technology. His research continues to combine cell reprogramming technology, genome editing/analysis tools and microfluidic/nanoparticle based detection/ delivery technologies with the aim of creating human in vitro models of disease, unravel the underlying gene regulatory networks and enable novel cell- and delivery-based therapeutics, respectively. He further co-direct the UQ-Centre for stem cell ageing and regenerative engineering (UQ-StemCARE).

Dr Jian Zeng is a statistical geneticist and NHMRC Emerging Leadership Fellow at the Institute for Molecular Bioscience (IMB) at the University of Queensland (UQ). He received his PhD in animal breeding and genetics at Iowa State University and joined the Program in Complex Trait Genomics (PCTG) at UQ in 2016. His research focuses on the development and application of innovative statistical methods for estimating the genetic architecture and evolutionary signals in complex traits, identifying genetic variants, genes and other molecular intermediates associated with phenotype variation, and predicting trait phenotypes using genome sequence data. In 2019, he was awarded an NHMRC Investigator Emerging Leadership Grant to develop statistical methods and software tools for best predict an individual’s disease risk using genomic and omics data. He was an invited speaker at the prestigious Gordon Research Conference in 2019.